247 related articles for article (PubMed ID: 26016820)
1. A novel once-daily fixed-dose combination of memantine extended release and donepezil for the treatment of moderate to severe Alzheimer's disease: two phase I studies in healthy volunteers.
Boinpally R; Chen L; Zukin SR; McClure N; Hofbauer RK; Periclou A
Clin Drug Investig; 2015 Jul; 35(7):427-35. PubMed ID: 26016820
[TBL] [Abstract][Full Text] [Related]
2. A fixed-dose combination of memantine extended-release and donepezil in the treatment of moderate-to-severe Alzheimer's disease.
Deardorff WJ; Grossberg GT
Drug Des Devel Ther; 2016; 10():3267-3279. PubMed ID: 27757016
[TBL] [Abstract][Full Text] [Related]
3. Memantine and donepezil: a fixed drug combination for the treatment of moderate to severe Alzheimer's dementia.
Owen RT
Drugs Today (Barc); 2016 Apr; 52(4):239-48. PubMed ID: 27252988
[TBL] [Abstract][Full Text] [Related]
4. Memantine ER/Donepezil: A Review in Alzheimer's Disease.
Greig SL
CNS Drugs; 2015 Nov; 29(11):963-70. PubMed ID: 26519339
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of donepezil 23 mg versus donepezil 10 mg for moderate-to-severe Alzheimer's disease: a subgroup analysis in patients already taking or not taking concomitant memantine.
Doody RS; Geldmacher DS; Farlow MR; Sun Y; Moline M; Mackell J
Dement Geriatr Cogn Disord; 2012; 33(2-3):164-73. PubMed ID: 22572767
[TBL] [Abstract][Full Text] [Related]
6. An evaluation of memantine ER + donepezil for the treatment of Alzheimer's disease.
Calhoun A; King C; Khoury R; Grossberg GT
Expert Opin Pharmacother; 2018 Oct; 19(15):1711-1717. PubMed ID: 30244611
[TBL] [Abstract][Full Text] [Related]
7. Concurrent administration of donepezil HCl and sertraline HCl in healthy volunteers: assessment of pharmacokinetic changes and safety following single and multiple oral doses.
Nagy CF; Kumar D; Perdomo CA; Wason S; Cullen EI; Pratt RD
Br J Clin Pharmacol; 2004 Nov; 58 Suppl 1(Suppl 1):25-33. PubMed ID: 15496220
[TBL] [Abstract][Full Text] [Related]
8. Concurrent administration of donepezil HCl and levodopa/carbidopa in patients with Parkinson's disease: assessment of pharmacokinetic changes and safety following multiple oral doses.
Okereke CS; Kirby L; Kumar D; Cullen EI; Pratt RD; Hahne WA
Br J Clin Pharmacol; 2004 Nov; 58 Suppl 1(Suppl 1):41-9. PubMed ID: 15496222
[TBL] [Abstract][Full Text] [Related]
9. Cost-effectiveness of memantine in moderate-to-severe Alzheimer's disease patients receiving donepezil.
Weycker D; Taneja C; Edelsberg J; Erder MH; Schmitt FA; Setyawan J; Oster G
Curr Med Res Opin; 2007 May; 23(5):1187-97. PubMed ID: 17519086
[TBL] [Abstract][Full Text] [Related]
10. Lack of pharmacokinetic or pharmacodynamic interaction between memantine and donepezil.
Periclou AP; Ventura D; Sherman T; Rao N; Abramowitz WT
Ann Pharmacother; 2004 Sep; 38(9):1389-94. PubMed ID: 15266045
[TBL] [Abstract][Full Text] [Related]
11. The clinical and cost-effectiveness of donepezil, rivastigmine, galantamine and memantine for Alzheimer's disease.
Loveman E; Green C; Kirby J; Takeda A; Picot J; Payne E; Clegg A
Health Technol Assess; 2006 Jan; 10(1):iii-iv, ix-xi, 1-160. PubMed ID: 16409879
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetic comparison of orally disintegrating and conventional donepezil formulations in healthy Korean male subjects: a single-dose, randomized, open-label, 2-sequence, 2-period crossover study.
Kim KA; Lim JL; Kim C; Park JY
Clin Ther; 2011 Jul; 33(7):965-72. PubMed ID: 21723605
[TBL] [Abstract][Full Text] [Related]
13. Safety and tolerability of donepezil at doses up to 20 mg/day: results from a pilot study in patients with Alzheimer's disease.
Doody RS; Corey-Bloom J; Zhang R; Li H; Ieni J; Schindler R
Drugs Aging; 2008; 25(2):163-74. PubMed ID: 18257603
[TBL] [Abstract][Full Text] [Related]
14. Memantine extended release (28 mg once daily): a review of its use in Alzheimer's disease.
Plosker GL
Drugs; 2015 May; 75(8):887-97. PubMed ID: 25899711
[TBL] [Abstract][Full Text] [Related]
15. Bioequivalence study of two different tablet formulations of donepezil using truncated areas under the curve. A single-center, single-dose, randomized, open-label, 2-way crossover study under fasting conditions.
Almeida S; Filipe A; Neves R; Desjardins I; Shink E; Castillo A
Arzneimittelforschung; 2010; 60(3):116-23. PubMed ID: 20422942
[TBL] [Abstract][Full Text] [Related]
16. The efficacy and safety of memantine for the treatment of Alzheimer's disease.
Matsunaga S; Kishi T; Nomura I; Sakuma K; Okuya M; Ikuta T; Iwata N
Expert Opin Drug Saf; 2018 Oct; 17(10):1053-1061. PubMed ID: 30222469
[TBL] [Abstract][Full Text] [Related]
17. [Bioequivalence of donepezil capsule and tablet in human].
Hao XY; Ding L; Li LM; Bian XJ; Zhang SQ
Yao Xue Xue Bao; 2003 May; 38(5):392-4. PubMed ID: 12958848
[TBL] [Abstract][Full Text] [Related]
18. Higher-dose (23 mg/day) donepezil formulation for the treatment of patients with moderate-to-severe Alzheimer's disease.
Christensen DD
Postgrad Med; 2012 Nov; 124(6):110-6. PubMed ID: 23322144
[TBL] [Abstract][Full Text] [Related]
19. Effect of food on the pharmacokinetics of oxycodone and naltrexone from ALO-02, an extended release formulation of oxycodone with sequestered naltrexone.
Gandelman K; Lamson M; Salageanu J; Bramson C; Matschke K; Malhotra B
Clin Pharmacol Drug Dev; 2015 Sep; 4(5):370-6. PubMed ID: 27137146
[TBL] [Abstract][Full Text] [Related]
20. Treatment effects between monotherapy of donepezil versus combination with memantine for Alzheimer disease: A meta-analysis.
Chen R; Chan PT; Chu H; Lin YC; Chang PC; Chen CY; Chou KR
PLoS One; 2017; 12(8):e0183586. PubMed ID: 28827830
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
